Cargando…

Why Some Patients Undergoing Lipoprotein Apheresis Therapy Develop New Cardiovascular Events?

Lipoprotein apheresis (LA) is an effective tool to reduce cardiovascular events (CVEs) in high-risk patients with elevations of low density lipoprotein-cholesterol (LDL-C) and/or Lipoprotein(a) (Lp(a)). All patients included into this retrospective analysis had experienced CVEs before the start of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Julius, Ulrich, Kuss, Solveig, Tselmin, Sergey, Schatz, Ulrike, Bornstein, Stefan R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569841/ https://www.ncbi.nlm.nih.gov/pubmed/32708542 http://dx.doi.org/10.3390/jcdd7030025

Ejemplares similares

Current Role of Lipoprotein Apheresis in the Treatment of High-Risk Patients
por: Julius, Ulrich
Publicado: (2018)

Lipoprotein apheresis in the management of severe hypercholesterolemia and of elevation of lipoprotein(a): current perspectives and patient selection
por: Julius, Ulrich
Publicado: (2016)

Clinical improvement of Long-COVID is associated with reduction in autoantibodies, lipids, and inflammation following therapeutic apheresis
por: Achleitner, Martin, et al.
Publicado: (2023)

Familial Hypercholesterolemia and Lipoprotein Apheresis
por: Makino, Hisashi, et al.
Publicado: (2019)

Current Role of Lipoprotein Apheresis
por: Thompson, Gilbert, et al.
Publicado: (2019)

Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19
por: Vuorio, Alpo, et al.
Publicado: (2021)

Chronic post-COVID-19 syndrome and chronic fatigue syndrome: Is there a role for extracorporeal apheresis?
por: Bornstein, Stefan R., et al.
Publicado: (2021)

The German Lipoprotein Apheresis Registry (GLAR) – almost 5 years on
por: Schettler, V. J. J., et al.
Publicado: (2017)

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial
por: Moriarty, Patrick M., et al.
Publicado: (2016)

Lipoprotein apheresis results in plaque stabilization and prevention of cardiovascular events: comments on the prospective Pro(a)LiFe study
por: Klingel, Reinhard, et al.
Publicado: (2015)

Lipoprotein(a) Lowering—From Lipoprotein Apheresis to Antisense Oligonucleotide Approach
por: Greco, Maria Francesca, et al.
Publicado: (2020)

Case report: lipoprotein apheresis reduces the risk of cardiovascular events and prolongs pregnancy in a woman with severely elevated lipoprotein(a), cardiovascular disease, and a high risk of preeclampsia
por: Marlȩga-Linert, Joanna, et al.
Publicado: (2023)

Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels
por: Schettler, Volker J. J., et al.
Publicado: (2015)

Activation of Lipid Mediator Formation Due to Lipoprotein Apheresis
por: Weylandt, Karsten-H., et al.
Publicado: (2019)

Lipoprotein apheresis efficacy and challenges: single center experience
por: Özdemir, Zehra Narlı, et al.
Publicado: (2022)

Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis center
por: Mickiewicz, Agnieszka, et al.
Publicado: (2020)

The Impact of Lipoprotein Apheresis on Oxidative Stress Biomarkers and High-Density Lipoprotein Subfractions
por: Mickiewicz, Agnieszka, et al.
Publicado: (2020)

Lipoprotein-apheresis reduces circulating microparticles in individuals with familial hypercholesterolemia
por: Connolly, Katherine D., et al.
Publicado: (2014)

Flaxseed (Linum Usitatissimum L.) Supplementation in Patients Undergoing Lipoprotein Apheresis for Severe Hyperlipidemia—A Pilot Study
por: Kanikowska, Dominika, et al.
Publicado: (2020)

Comparison of plasma separation using centrifugation or filtration for MONET lipoprotein apheresis in patients with cardiovascular disease and severe dyslipidemia
por: Waitz, Grit, et al.
Publicado: (2022)

The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein(a) in ischaemic heart disease and refractory angina
por: Khan, Tina Z, et al.
Publicado: (2014)

Use of CMR imaging to assess the effect of lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a)
por: Khan, Tina, et al.
Publicado: (2015)

Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease
por: Heigl, Franz, et al.
Publicado: (2015)

Changes in Lipids and Lipoproteins after Selective LDL Apheresis (7-Year Experience)
por: Kolovou, Genovefa, et al.
Publicado: (2012)

Pregnancy in a Woman with Homozygous Familial Hypercholesterolemia Not on Low-Density Lipoprotein Apheresis
por: Fahed, Akl C., et al.
Publicado: (2012)

Systematic Review of Low‐Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia
por: Wang, Anthony, et al.
Publicado: (2016)

Improvement of oxidative stress status by lipoprotein apheresis in Chinese patients with familial hypercholesterolemia
por: Wen, Jun, et al.
Publicado: (2019)

Lipoprotein glomerulopathy treated with LDL-apheresis (Heparin-induced Extracorporeal Lipoprotein Precipitation system): a case report
por: Russi, Gianpaolo, et al.
Publicado: (2009)

Lipoprotein turnover and possible remnant accumulation in preeclampsia: insights from the Freiburg Preeclampsia H.E.L.P.-apheresis study
por: Contini, Christine, et al.
Publicado: (2018)

Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines
por: Klingel, Reinhard, et al.
Publicado: (2017)

HELP apheresis in hypercholesterolemia and cardiovascular disease: efficacy and adverse events after 8,500 procedures
por: Buuren, Frank van, et al.
Publicado: (2012)

Hypertriglyceridaemia: contemporary management of a neglected cardiovascular risk factor
por: Khan, Tina Z., et al.
Publicado: (2021)

Desialylation of platelet surface glycans enhances platelet adhesion to adsorbent polymers for lipoprotein apheresis
por: Lauková, Lucia, et al.
Publicado: (2020)

Low‐density lipoprotein apheresis is associated with removal of SARS‐CoV‐2 antibodies
por: Bertram, Sebastian, et al.
Publicado: (2022)

Lipoprotein(a)-hyperlipoproteinemia as cause of chronic spinal cord ischemia resulting in progressive myelopathy – successful treatment with lipoprotein apheresis
por: Heigl, Franz, et al.
Publicado: (2017)

LDL Apheresis and Lp (a) Apheresis: A Clinician’s Perspective
por: Kayikcioglu, Meral
Publicado: (2021)

Adverse events associated with apheresis procedures: Incidence and relative frequency
por: Philip, Joseph, et al.
Publicado: (2013)

Long-term Low-density Lipoprotein Apheresis in a Patient with Refractory Idiopathic Membranous Glomerulonephritis
por: Yabuuchi, Junko, et al.
Publicado: (2017)

Favorable therapeutic efficacy of low‐density lipoprotein apheresis for nephrotic syndrome with impaired renal function
por: Muso, Eri, et al.
Publicado: (2021)

Lipoprotein(a): the underutilized risk factor for cardiovascular disease
por: Khan, TZ, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_t6ufqhkqi71535q63kmd5vumos